w we go to phase three, which asks the question, can we approve it and for what indications? So instead of one big obesity trial, Lilly designed Triumph, which is four coordinated phase three trials. So what are we studying? Number one is obesity without type two diabetes. Number two is obesity with type two diabetes. Number three is obesity with cardiovascular disease. And number four is obesity with knee osteoarthritis. Triumph four is completed. We only have the press release. If you're bored, you can go. Last but not least on the NOVA side, we have the phase two dose ranging trial, which ended at 24 weeks. So of course these trials aren't identical and they don't have identical doses. So to compare them fairly, I put together some charts so we can look at the full range of results. All right. So starting with the phase two trial, 338 patients. And remember it was obesity without type two diabetes. So the trial tested four different doses 1, 4, 8, and 12 and two different endpoints 24 weeks and 48 weeks. Just to clarify mean percent weight loss is the average percent change from baseline and it's reported as least square mean which is an adjusted average from the trial statistical model. I have to say that. So look at 24 weeks clean dose response at 48 weeks it keeps dropping just look at 24 weeks, clean dose response. At 48 weeks, it keeps dropping. Just look at the 12 milligrams from 17.5 to 24.2. So the takeaway is simple, dose-dependent weight loss, and it continues over time. This is why durability matters. Next up, we have our phase three triumph four results, the only ones that are in. This was 68 weeks, and it looked at nine and 12 milligram doses. As we all know, what's incredible here is that the weight loss did not plateau, continuing out to 68 weeks. All right, now we're going to add on the Novo data. You can also ask the question, Jackie, why don't they just do the same doses each time? That's for another video. All right, this is the GGG, UBT 251. Around 200 patients with either obesity or who are overweight with at least one related comorbidity. So they dosed at two, four, and six, and they only reported the six. Mean weight loss was 19.7% compared to the placebo of two. Remember, this is at 24 weeks. Now let's put this all together. On the Lilly side, we have multiple time points so we can kind of watch the weight change over time. But if we want to compare the Novo at 24 weeks to Lilly, the best thing to use is the eight or 12 milligrams. So statistically speaking, and I mean this in the most basic non-overstating way, to use is the 8 or 12 milligrams. So statistically speaking, and I mean this in the most basic non-overstating way, if we compare the 6 and 8 milligrams, there's a 2.4 point percent difference. That's interesting, but it's not enough to call it better. Just for starters, different populations, different trial design, different titration. I know this might not be dramatic, but this is what real drug development looks like. I think the drama is Novo's still in the race, Lilly's obviously winning. I think it's actually fascinating to watch these curves move over time. What's more interesting is HCC data. I'll do that maybe another time. The trial designs are complicated.